Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Effects of K201 Injection, 2 mg/mL on the Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation
NCT00626652 is registered in ClinicalTrials.gov with Sequel Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Effects of K201 Injection, 2 mg/mL on the Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation
- Lead sponsor
- Sequel Pharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- December 31, 2009
- Enrollment
- 153 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.